TABLE 1.
Cancer-associated expression of Fn14.
| Tumor entity | Remark | References |
|---|---|---|
| Breast cancer | Fn14 expression correlated with poor prognosis | Willis et al. (2008) |
| Association between Fn14 and HER2 expression | ||
| Fn14 expression in 148 of 171 cases (86.5%) | Wang et al. (2013) | |
| Luminal breast carcinoma | Fn14 expression prognostic for brain metastasis | Martinez-Aranda et al. (2015), Martinez-Aranda et al. (2017) |
| Colorectal cancer | Fn14 expression in 75% (128/171) of primary colorectal tumors, in 76% (62/82) of colorectal tumors with liver metastases but only in 7% (2/29) of normal colorectal tissues | Culp et al. (2010) |
| Endometrial cancer | Fn14 upregulation | Wang et al. (2010) |
| Esophageal adenocarcinoma | Fn14 upregulation | Watts et al. (2007) |
| Esophageal cancer | Fn14 expression in 10 of 43 cases (23.2%) | Yoriki et al. (2011) |
| Gastric cancer | Fn14 expression inversely correlated with survival | Kwon et al. (2012) |
| Glioblastoma multiforme (GBM) | Fn14 expression increases with tumor grade | Tran et al. (2003) |
| Recurrent GBM, Gliosarcoma | Fn14 in recurrent GBM higher than in matched primary | Hersh et al. (2018a) |
| Glioma | Fn14 reduced disease-free survival | Tan et al. (2018), Connolly et al. (2021), Tao et al. (2022) |
| Fn14 expression correlates with high plasminogen activator inhibitor-1 expression | ||
| Neuroblastoma | Fn14 expression higher in primary high stage tumors compared to low stage tumors | Pettersen et al. (2013) |
| Head and neck squamous cell carcinoma | Fn14 expression associated with poorprognosis | Aye et al. (2021) |
| Hepatocellular cancer | Fn14 expression in 142 of 260 cases (54.6%) | Li et al. (2013) |
| Non-small cell lung cancer | 48.6% of adenocarcinoma Fn14+ | Whitsett et al. (2012) |
| 31.5% of squamous cell carcinoma Fn14+ | ||
| Non-small cell lung cancer | Fn14 expression associated with higher mortality | Wang et al. (2021) |
| Small cell lung cancer | Fn14 expression in 26 of 51 cases (50.98%) | Li et al. (2014) |
| Fn14 expression associated with poor pathologic stage | ||
| Melanoma | Fn14 expression in 173 of 190 cases (92%) of primary melanoma and in 86 of 150 cases (58%) of melanoma metastases | Zhou et al. (2013a) |
| Oral squamous cell carcinoma | 90% positive | Acharya et al. (2019) |
| Ovarian cancer | Fn14 expression in 73% (48/66) of ovarian cancer but 0% (0/2) in normal ovarian tissue | Culp et al. (2010) |
| Ovarian cancer | Fn14 expression in 35 of 41 cases (85.37%) | Gu et al. (2013) |
| Pancreatic cancer | Fn14 expression in 35 of 51 cases (68.6 5) pancreatic cancer. | Yoriki et al. (2011) |
| Pancreatic cancer | Fn14 expression in 79% (37/47) of pancreatic tumors but only in 17% (1/6) of normal pancreatic tissues | Culp et al. (2010) |
| Prostate cancer | 10% of normal prostate epithelium Fn14 + but >75% of metastatic samples Fn14+ | Yin et al. (2014) |
| Fn14 expression inversely correlated with androgen receptor expression | ||
| Prostate cancer | High expression of Fn14 associated with higher prostate-specific antigen recurrence rate after radical prostatectomy | Huang et al. (2011) |
| Thyroid cancer | Fn14 expression associated cancer risk | Lian et al. (2020) |